News

April 28, 2020April 28, 2020

Study: Opdivo-Cabometyx Combo Extends Survival, Increases Response Rates in Advanced Kidney Cancer

News

Combining Cabometyx (cabozantinib) with Opdivo (nivolumab) significantly extends survival, delays disease progression and increases the rate of positive responses compared to standard treatment with Sutent (sunitinib) among people with newly diagnosed advanced ... Read more

April 27, 2020April 27, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

News, syndicated

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their ... Read more

April 21, 2020April 21, 2020

Bavencio Seen as Ineffective in Phase 3 Head and Neck Cancer Trial

News

A Phase 3 trial of Bavencio (avelumab) in people with squamous cell carcinoma of the head and neck (SCCHN) was ended early due to a lack of effectiveness seen in ... Read more

April 14, 2020April 14, 2020

Balstilimab, Potential Cervical Cancer Treatment, Placed on Fast Track

News

The U.S. Food and Drug Administration (FDA) has now given fast track status to Agenus’ balstilimab — both alone and in combination — as an immunotherapy candidate for advanced metastatic cervical cancer. This designation, given ... Read more

April 7, 2020April 7, 2020

Early Success in Phase 3 Trial of Sacituzumab Govitecan in Triple-Negative Breast Cancer

News

A Phase 3 clinical trial investigating Immunomedics‘ potential therapy sacituzumab govitecan is ending early because existing results have shown sufficient evidence that the treatment is effective in patients with triple-negative ... Read more

March 31, 2020March 31, 2020

FDA Approves Imfinzi-Chemo Combo to Treat Advanced SCLC

News

The U.S. Food and Drug Administration (FDA) has approved Imfinzi (durvalumab), in combination with standard chemotherapy, as an initial treatment of people with extensive-stage small cell lung cancer (SCLC). This decision was ... Read more

March 24, 2020March 31, 2020

Imfinzi Plus Chemo Extends Survival in Advanced Small Cell Lung Cancer, Trial Analysis Shows

News

First-line treatment with Imfinzi (durvalumab) combined with standard chemotherapy significantly prolongs the life of people with extensive-stage small cell lung cancer (SCLC), final results of the CASPIAN Phase 3 trial ... Read more

March 23, 2020March 23, 2020

Better Responses with IO102-Keytruda Combo Likely in Ongoing NSCLC Trial

News

Adding IO Biotech’s lead candidate, IO102, to first-line treatment with Keytruda (pembrolizumab) is likely to result in better response rates in people with metastatic non-small cell lung cancer (NSCLC), an interim analysis ... Read more

March 20, 2020March 20, 2020

Harbour BioMed Gets FDA Nod to Start US Trials of 2 Immunotherapies

News

The U.S. Food and Drug Administration (FDA) has approved Harbour BioMed’s investigational new drug applications to initiate U.S. clinical trials testing two of its immunotherapy candidates — HBM9167 and HBM4003 — in ... Read more

March 18, 2020April 1, 2020

FDA Approves Opdivo-Yervoy Combo for Previously Treated Liver Cancer

News

The U.S. Food and Drug Administration (FDA) approved a combination of Bristol-Myers Squibb‘s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of hepatocellular carcinoma (HCC) patients who ... Read more